Start Date
December 31, 2010
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
Lapatinib
Lapatinib 1000 mg orally once daily continuously
Trastuzumab
Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
Epirubicin
Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
Cyclophosphamide
Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
Paclitaxel
Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
GSK Investigational Site, Budapest
GSK Investigational Site, Gyula
GSK Investigational Site, Castellon
GSK Investigational Site, Graz
GSK Investigational Site, Oslo
GSK Investigational Site, Oslo
Lead Sponsor
GlaxoSmithKline
INDUSTRY